AAN 2025 | Novel agents and approaches being explored for the treatment of Parkinson’s disease
Harini Sarva, MD, Weill Cornell Medicine, New York, NY, comments on novel agents that are being explored for the treatment of Parkinson’s disease. She highlights the upcoming Phase III trial of bemdaneprocel, as well as the continuous use of subcutaneous pumps. Dr Sarva then goes on to discuss the use of MRI-guided focused ultrasound to identify novel targets. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah there’s several, so again there’s the Phase III for the bemdaneprocel trial that’s going to be launching, there’s additional gene therapy trials that are either ongoing or will be launched soon along with additional cell therapy trials. The continuous use of the subcutaneous pumps. There’s already one subcutaneous carbidopa levodopa pump that’s been FDA approved and a subcutaneous apomorphine pump that’s been FDA approved...
Yeah there’s several, so again there’s the Phase III for the bemdaneprocel trial that’s going to be launching, there’s additional gene therapy trials that are either ongoing or will be launched soon along with additional cell therapy trials. The continuous use of the subcutaneous pumps. There’s already one subcutaneous carbidopa levodopa pump that’s been FDA approved and a subcutaneous apomorphine pump that’s been FDA approved. So it’ll be interesting to see the real world data for those two. The MRI guided focused ultrasound is looking at new targets and new conditions. So that’s always exciting as well. And we’re waiting to on the data for the most recent focused ultrasound trial. So there’s a lot of very interesting stuff that’s going on, both for symptomatic therapies, but there’s also disease-modifying therapies that are under investigation as well, including LARC-2 inhibitors, new therapies for GBA Parkinson’s. So it’s an exciting time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
I received research support for my work on clinical trials from Biogen, Meira GTX, Sun Pharma, Bukwang, Genentech, Prevail, BlueRock, Neuroderm, UCB, Cerevance and Novo Nordisk.
